US 6,982,089 B2
Cytokine antagonists for neurological and neuropsychiatric disorders
Edward Lewis Tobinick, Los Angeles, Calif. (US)
Assigned to TACT IP, LLC, Highland Beach, Fla. (US)
Filed on Oct. 09, 2002, as Appl. No. 10/269,745.
Application 10/269745 is a continuation in part of application No. 10/236097, filed on Sep. 06, 2002, abandoned.
Application 10/236097 is a continuation in part of application No. 09/841844, filed on Apr. 25, 2001, granted, now 6,537,549.
Application 09/841844 is a continuation in part of application No. 09/826976, filed on Apr. 05, 2001, granted, now 6,419,944.
Application 09/826976 is a continuation in part of application No. 09/563651, filed on May 02, 2000, granted, now 6,471,961.
Application 09/563651 is a continuation in part of application No. 09/476643, filed on Dec. 31, 1999, granted, now 6,177,077.
Application 09/476643 is a continuation in part of application No. 09/275070, filed on Mar. 23, 1999, granted, now 6,015,557.
Application 09/275070 is a continuation in part of application No. 09/256388, filed on Feb. 24, 1999, abandoned.
Prior Publication US 2003/0049256 A1, Mar. 13, 2003
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 39/40 (2006.01)
U.S. Cl. 424—400 15 Claims
 
1. A method for treating TNF mediated dementias, being Alzheimer's Disease, Pick's Disease, Lewy Body Disease and Idiopathic Dementia, in a human by inhibiting the action of tumor necrosis factor (TNF) through the administration of a TNF antagonist comprising the steps of:
a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, soluble TNF receptor Type I, pegylated soluble TNF receptor Type I (PEGs TNF-R1) and onercept, a recombinant TNF binding protein (r-TBP-1) (Serono); and
b) administering said dose parenterally by perispinal administration into the perispinal space without direct intrathecal injection.